Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 104 results for melanoma

  1. Cancer: invasive cancer diagnosed via emergency routes (IND1)

    This indicator covers the proportion of invasive cases of cancer diagnosed via an emergency route. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCC01

    Network / system level indicators
    Last updated
    31 October 2023

  2. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838

    Awaiting development [GID-TA11275] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (IPG785)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

    Interventional procedures guidance
    Published
    16 April 2024
    View recommendations

    Sections for IPG785

  4. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

    Technology appraisal guidance
    Published
    28 April 2021
    View recommendations

    Sections for TA692

  5. Vandetanib for treating medullary thyroid cancer (TA550)

    Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.

    Technology appraisal guidance
    Published
    12 December 2018
    View recommendations

    Sections for TA550

  6. Cabozantinib for treating medullary thyroid cancer (TA516)

    Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.

    Technology appraisal guidance
    Published
    28 March 2018
    View recommendations

    Sections for TA516

  7. Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab would be encouraged because it could provide information for future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line treatment.

    Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma Number TA319 Date issued July 2014 Other details

    Research recommendation
    Published
    9 June 2015

  8. Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

    In development [GID-TA10577] Expected publication date: 21 April 2021

    Technology appraisal guidance
    In development

  9. Surgical excision for people with lentigo maligna: For people with lentigo maligna (stage 0 in sun damaged skin, usually on the face) how effective is Mohs micrographic surgery, compared with excision with a 0.5 cm clinical margin, in preventing biopsy proven local recurrence at 5 years? This should be investigated in a randomised controlled trial. Secondary outcomes should include cosmetic and functional outcomes.

    adjacent skin. Source guidance details Comes from guidance Melanoma: assessment and management Number NG14 Date issued

    Research recommendation
    Published
    4 August 2022

  10. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued [GID-TAG479]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA830

  12. Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

    NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer

    Medtech innovation briefing
    Published
    24 August 2016

  13. Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)

    Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA802

  14. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued [GID-TA10267]

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    30 September 2020
    View recommendations

    Sections for TA650